Veslugen
Also known as: Vesugen, KED
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
Synthetic KED tripeptide researched as a vascular bioregulator
Status
Preclinical
Typical dose
10–20mg
Researched for
Circulatory health, vascular support, aging
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
Preclinical - Promising animal research, limited human data
Use the tools
Stay current
Get updates on Veslugen
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Veslugen is described as a vendor spelling for Vesugen, the synthetic tripeptide KED.
- The source frames it as a vascular bioregulator from the Khavinson program.
- Evidence is listed as , with no FDA approval and no registered randomized human trials reported.
- Source dosing entries report 10-20 mg daily, once or twice daily, using oral capsules or sublingual administration.
- Research areas include circulatory health, vascular support, and aging.
How it's thought to work
Veslugen/KED is proposed to act through gene-regulatory effects rather than a conventional receptor target. The cited source describes a hypothesis in which the short enters cells, localizes near nuclear DNA, and changes promoter activity linked to vascular biology. Reported mechanistic work includes molecular docking near MKI67 and experimental observations involving endothelial markers such as endothelin-1, connexins, sirtuin-1, and . The evidence described is largely computational, , animal-based, and concentrated within one research lineage.
What the research shows
Where the research stands
The source describes KED as a defined ultrashort discussed in peer-reviewed Khavinson-related literature, including review material that mentions vascular and blood-brain-barrier biology in cell and animal contexts. Reported findings include gene-expression changes, stimulation, and normalization of endothelial markers, but the source characterizes the evidence as mostly , molecular docking, and aged-animal work. Human evidence is described as very limited and not based on rigorous placebo-controlled trials, with little independent replication outside the originating research group.
What it shows
✓ Animal studies
Promising animal research, limited human data
△ Limitations
Animal study doses may not translate directly to humans.
Bottom line: Preclinical research; reported as approved in Russia as a supplement Not FDA approved
Typical dosing
CommunityCommunity dataset10–20 mg
daily
Community-reported dosing for vascular or circulatory bioregulator use; not established as a clinical dosing standard.
Research dosing
Animal studies onlyAnimal studies only - may not translate to humans
Doses observed in studies
10-20 mg daily
Animal study doses may not translate directly to humans.
- Duration
- 10-30 day cycles
- Administration
- Oral capsules or sublingual
Timing & administration
Best time to take
Morning on an empty stomach
Once or twice daily
Food recommendation
Take on an empty stomach
Why this timing?
The source links fasted timing to the general absorption rationale used for peptide bioregulators.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Generally well tolerated
- Limited safety data outside Russia
- Not FDA approved
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
Frequently asked questions
Sequence
Lys-Glu-Asp (KED)
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.